CAMK2D causes heart failure in mice with RBM20 cardiomyopathy.

Summary

Using genetic mouse models and pharmacologic inhibition, the study demonstrates that CAMK2D overactivation—not merely mis-splicing—drives cardiac dysfunction in RBM20 cardiomyopathy. Double knockout of Rbm20 and Camk2d rescues heart failure/sudden death, re-expression of CAMK2D isoforms reintroduces dysfunction, and CAMK2 inhibition (hesperadin) improves cardiac function in RBM20 mutant mice.

Key Findings

• Rbm20/Camk2d double knockout mice were protected from heart failure and sudden cardiac death.
• RBM20-deficient hearts showed increased phosphorylation of CAMK2D targets, indicating functional activation.
• Re-expression of individual CAMK2D splice variants reintroduced cardiac dysfunction.
• ATP-competitive CAMK2 inhibitor hesperadin improved cardiac function in Rbm20-p.Arg636Gln knock-in mice.

Clinical Implications

Supports development of CAMK2D inhibitors for RBM20 cardiomyopathy and encourages genotype-guided trials testing CAMK2 pathway blockade as a precision therapy.

Limitations

• Preclinical mouse models may not fully capture human disease heterogeneity.
• Target selectivity and safety of CAMK2 inhibition (e.g., hesperadin off-target effects) require clinical evaluation.

Future Directions

Initiate genotype-guided phase I/II trials of selective CAMK2D inhibitors in RBM20 cardiomyopathy; elucidate translational biomarkers of CAMK2D activity and arrhythmic risk modulation.